X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PMC-403 is an antibody therapeutic candidate with a novel mechanism of action in which it activates the TIE2 receptor and normalizes the leaky pathological blood vessels, which is investigated for the treatment of Neovascular Age-related Macular Degeneration.
Lead Product(s): PMC-403
Therapeutic Area: Ophthalmology Product Name: PMC-403
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. Once the molecule binds to the receptors, it promotes the normalization and stabilization of pathologically leaky blood vessels.
Lead Product(s): PMC-403
Therapeutic Area: Ophthalmology Product Name: PMC-403
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.
Lead Product(s): PMC-309,Pembrolizumab
Therapeutic Area: Oncology Product Name: PMC-309
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 12, 2022
Details:
Olinvacimab (TTAC-0001), an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) fully human antibody, is in clinical stage for mTNBC and rGBM. It has an ongoing Phase II olinvacimab and pembrolizumab combo study for the treatment of mTNBC in Australia.
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform from RNAGENE.
Lead Product(s): mRNA-based Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: RNAGENE Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 21, 2022
Details:
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™' to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies.
Lead Product(s): mRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: NuclixBio Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2022
Details:
PharmAbcine and MSD decided to enter this collaboration based on the promising clinical data obtained from the Phase Ib olinvacimab and pembrolizumab study in mTNBC which is still ongoing in Australia.
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
Details:
This unique mechanism allows PMC-403 to be a potent therapeutic drug for pathological vessel-related diseases in both ocular and non-ocular areas.
Lead Product(s): PMC-403
Therapeutic Area: Ophthalmology Product Name: PMC-403
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
Olinvacimab, an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptors-2) molecule, is the company's lead asset. The molecule is currently undergoing multiple global clinical trials.
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The phase II clinical trial will enroll immuno-oncology drug naïve mTNBC patients regardless of their PD-L1 expression level to check the efficacy, safety, pharmacodynamics, and expression of VEGFR-2 and PD-L1 after giving 16mg/kg of olinvacimab and 200mg of pembrolizumab.
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
